TRBN

February 5, 2012

Biotech Baker’s Dozen to Watch at Hematology Meeting

November 29, 2009 By MD Becker Partners 2 Comments

The 51st American Society of Hematology [ASH] Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. This is the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals. In this regard, Celgene Corporation (CELG) recently announced that data from [...]

Filed Under: Articles Tagged With: AEterna Zentaris, AEZS, Allos Therapeutics, ALTH, American Society of Hematology, ARIA, ARIAD Pharmaceuticals, Calistoga Pharmaceuticals, CELG, Celgene, chemotherapeutics, CYCC, Cyclacel Pharmaceuticals, Facet Biotech, FACT, GENT, Gentium SPA, HDAC inhibitors, IMGN, ImmunoGen, KaloBios Pharmaceuticals, kerx, Keryx Biopharmaceuticals, kinase inhibitors, monoclonal antibodies, nucleoside analogues, ONXX, Onyx Pharmaceuticals, PCYC, Pharmacyclics, pi3k, proteasome inhibitors, sapacitabine, Seattle Genetics, Semafore Pharmaceuticals, SGEN, small modular immunopharmaceuticals, SNSS, Sunesis Pharmaceuticals, TRBN, Trubion Pharmaceuticals